Sequential antibiotic therapy

Current Opinion in Infectious Diseases

Volumn 13, Issue 6, 2000, Pages 599-607

  Barlow, Gavin D ^a   Nathwani, Dilip ^a  

^a King's Cross Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFAMANDOLE; CEFRADINE; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; QUINOLONE DERIVATIVE; TRIMETHOPRIM;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BONE INFECTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; ENDOCARDITIS; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; HEALTH CARE QUALITY; HOSPITAL RUNNING COST; HUMAN; INFECTIOUS ARTHRITIS; NONHUMAN; OSTEOMYELITIS; PNEUMONIA; PRACTICE GUIDELINE; REVIEW; URINARY TRACT INFECTION;

EID: 0033662969     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200012000-00004     Document Type: Review

References (58)

1. The misuse of antibiotics
2. The management of infections and antibiotic therapy: A European survey
3. Sequential antimicrobial therapy. A realistic approach to cost-containment
4. Programs promoting timely sequential antimicrobial therapy: An American perspective
5. Economics of home intravenous services
6. Home intravenous antibiotic therapy
7. Economic impact of streamlining antibiotic administration
8. Oral ciprofloxacin. A pharmacoeconomic evaluation of its use in the treatment of serious infections
9. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics
10. Cost comparison of ciprofloxacin versus cefamandole. DICP
11. Why do patients with infection remain in hospital once changed to oral antibiotics?
12. Impact of new oral antibiotics on the treatment of infectious diseases
13. Five common fallacies in estimating the economic gains of early discharge
14. Cost-effectiveness of quinolones in hospitals and the community
15. Oral administration of antibiotics: A reasonable alternative to the parenteral route
16. Sequential antimicrobial therapy: Pharmacokinetic and pharmacodynamic considerations in sequential therapy
17. Enteric absorption of ciprofloxacin during the immediate postoperative period
18. How often is medication taken as prescribed? A novel assessment technique
19. Sequential antimicrobial therapy: The role of quinolones
20. Ouinolones
21. Intravenous to oral (IV-PO) anti-infective conversion therapy
22. Trimethoprim: A review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections
23. Clinical pharmacokinetics of clarithromycin
24. Doxycycline
25. β-Lactams: Penicillins
26. Other β-lactams
27. β-Lactams: Cephalosporins
28. Cefaclor revisited
29. Sequential therapy with intravenous or oral cephalosporins
30. Programs promoting timely sequential antimicrobial therapy: An American perspective
31. Time to clinical stability in patients hospitalised with community-acquired pneumonia. Implications for practice guidelines
32. A controlled trial of a critical care pathway for treatment of community acquired pneumonia
33. Strategies for early discharge of the hospitalised patient with community acquired pneumonia
34. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital
35. An information system to promote intravenous to oral medication conversion
36. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: Ciprofloxacin versus standard antibiotic therapy
37. Sequential antibiotic therapy: The right patient, the right time and the right outcome
38. Strategies to rationalise sepsis management: A review of 4 years experience in Dundee
39. What the SHO really does
40. Evidence-based medicine: Empiric antibiotic therapy in community-acquired pneumonia
41. A prospective observational study of 200 patients with community acquired pneumonia
42. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital
43. Community acquired pneumonia in adults: Guidelines for management
44. Early transition to oral antibiotic therapy for community-acquired pneumonia: Duration of therapy, clinical outcomes, and cost-analysis
45. Oral absorption of clarithromycin in acute illness and during convalescence in patients with community-acquired pneumonia
46. Reevaluation of outpatients with Streptococcus pneumoniae bacteraemia
47. Treatment guideline for nursing home-acquired pneumonia based on community practice
48. Prospective, randomised, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis
49. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelone-phritis in women: A randomised trial
50. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastin in the treatment of intra-abdominal infections
51. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy
52. Epidemiology and outcome of osteomyelitis in the era of sequential intravenous-oral therapy
53. Early switch from intravenous to oral antibiotics in hospitalised patients with infections: A 6-month prospective study